Industry Briefs: July 2, 2012

Published on: 

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.

Company News

Arena Pharmaceuticals and Eisai have received FDA approval for a new molecular entity, Belviq (lorcaserin hydrochloride), for treating chronic weight management. Read More

Astellas Pharma has received approval for a new molecular entity, Myrbetriq (mirabegron) extended-release, for treating adults with overactive bladder. Read More

Biogen Idec and Isis Pharmaceuticals have announced a global collaboration for an antisense program targeting myotonic dystrophy. Read More

Encap Drug Delivery has invested $2 million to expand its facilities, for equipment for product mixing and capsule-filling. Read More

GEA Pharma Systems has agreed to supply a continuous manufacturing line for solid-dose products to an undisclosed pharmaceutical company. Read More


Janssen-Cilag, a Johnson & Johnson subsidiary, has completed the acquisition of Corimmun, a privately held German-based drug-development company. Read More

Takeda Farmacêutica Brasil, a subsidiary of Takeda Pharmaceutical has completed its acquisition of Multilab. Read More

People News

Alnylam Pharmaceuticals has expanded its management team. The company has appointed Oved Amitay as vice-president, head of commercial; Akshay Vaishnaw as executive vice-president and chief medical officer; Jared Gollob as vice-president of clinical research; and Lubomir Nechev as vice-president of process sciences. Read More